Loading...
Predicting survival in urothelial cancer patients after immunotherapy using real-world data
Elumalai, T Aversa, C. Buijtenhuijs, B Conroy, Ruth Croxford, William Das, A. Doss, G. Enting, D. Kitetere, E. Sanderson, B.
Elumalai, T
Aversa, C.
Buijtenhuijs, B
Conroy, Ruth
Croxford, William
Das, A.
Doss, G.
Enting, D.
Kitetere, E.
Sanderson, B.
Citations
Altmetric:
Abstract
Background: Metastatic urothelial cancer patients can be treated with immune
checkpoint inhibitors (ICIs) in the first- and second-line settings. Real world data is
limited. Although there is a survival benefit with second-line ICIs, only 1 in 5 patients
experience a durable response. We conducted a multicentre analysis exploring prognostic
clinical parameters and their impact on progression-free (PFS) and overall
survival (OS).
Methods: Between March 2017 and February 2020, data for 208 metastatic urothelial
patients treated with single-agent pembrolizumab or atezolizumab were collected
retrospectively from 5 centres. PFS was defined as the time from the first date of
immunotherapy to disease progression or death from any cause. Clinical parameters
such as age, gender, performance status, smoking history, presence of visceral or liver
metastasis, haemoglobin level(Hb), lymphocyte count, neutrophil count, lactate dehydrogenase
levels (LDH) and PDL-1 status were collected. KaplaneMeier and Cox
hazard methods were used for survival analysis.
Results: Out of 208 patients, 26(12.5%) received first-line ICIs. Median PFS and OS
were 4.5 (range 3.5- 5.7) and 9.2 (range 7.4-10.5) months, respectively. On univariable
analysis for OS, liver metastasis, neutrophil count, neutrophil lymphocyte ratio, haemoglobin,
and LDH levels were independent prognostic factors.
Conclusion: In this large real world data set, we have demonstrated a strong association
between OS and known prognostic factors such as liver metastases and Hb level,
but interestingly novel factors, neutrophil, and lymphocyte count also. These parameters
could be used to create a stratification model, which, if independently validated,
could help in selecting patients with urothelial cancer who benefit from ICIs.
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 78.32 KB
Keywords
Type
Meetings and Proceedings
Citation
Elumalai T, Aversa C, Buijtenhuijs B, Conroy R, Croxford W, Das A, et al. 765P Predicting survival in urothelial cancer patients after immunotherapy using real-world data. Annals of Oncology. 2020;31:S590-S.